For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies protect the transthyretin protein, preventing its damaging build-up and alleviating the impa